Karen Wilson Buys 10,000 Shares of Serina Therapeutics (NYSEAMERICAN:SER) Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Karen Wilson purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was bought at an average cost of $1.77 per share, for a total transaction of $17,700.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at $17,700. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Serina Therapeutics Price Performance

Serina Therapeutics stock traded down $0.06 during mid-day trading on Tuesday, hitting $1.92. The company’s stock had a trading volume of 97,959 shares, compared to its average volume of 2,884,637. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24. Serina Therapeutics, Inc. has a 52-week low of $1.22 and a 52-week high of $7.92. The stock’s 50 day moving average is $1.95. The firm has a market cap of $28.80 million, a P/E ratio of -0.96 and a beta of 1.15.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.